REZOLVE-AD
-
REZOLVE-AD Study: Rezpegaldesleukin Data Presented at ACAAI 2025
Nektar Therapeutics presented Phase 2b REZOLVE-AD data at ACAAI 2025, highlighting rezpegaldesleukin’s potential in atopic dermatitis and comorbid asthma. The study showed statistically significant reductions in Asthma Control Questionnaire (ACQ-5) scores in patients with both conditions. Notably, patients with poorly controlled asthma experienced even greater improvements. These findings suggest that rezpegaldesleukin, an IL-2 pathway agonist, may offer benefits beyond skin symptoms by promoting regulatory T-cell activity. Phase 3 trials are planned.
